Lipopolysaccharide Adsorption (Efferon LPS NEO) in Children With Sepsis

NACompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

March 3, 2025

Study Completion Date

April 30, 2025

Conditions
SepsisSeptic Shock
Interventions
DEVICE

Efferon LPS NEO

Efferon LPS NEO, a medical device, which is a cylindrical body filled with a polymeric hemosorbent that selectively absorbs LPS and excess cytokines. The device is used for extracorporeal therapy to relieve septic shock in the treatment of sepsis.

Trial Locations (7)

107014

Children's City Clinical Hospital named after St. Vladimir of the Moscow Department of Health, Moscow

119049

Morozovskaya Children's City Clinical Hospital of the Moscow City Healthcare Department, Moscow

119180

Clinical and Research Institute of Emergency Pediatric Surgery and Traumatology, Moscow

123001

Filatov Children's City Clinical Hospital of the Moscow Health Department, Moscow

123317

Children's City Clinical Hospital No. 9 named after G.N. Speransky of the Moscow City Health Department, Moscow

192289

Children's City Clinical Hospital No. 5 named after N.F.Filatov, Saint Petersburg

198205

Children's municipal multi-specialty clinical center of high medical technology, Saint Petersburg

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Ligand Research, LLC

NETWORK

lead

Efferon JSC

INDUSTRY

NCT05707494 - Lipopolysaccharide Adsorption (Efferon LPS NEO) in Children With Sepsis | Biotech Hunter | Biotech Hunter